A 61-year-old female was admitted as an emergency with hypercalcaemia and acute kidney injury (AKI). She had a past medical history of: hypertension, and thyrotoxicosis requiring total thyroidectomy (1980) . This procedure resulted in irreversible hypoparathyroidism requiring long-term treatment with calcium and vitamin D analogues. She had been commenced on hormone replacement therapy (HRT) in 1993 for post-menopausal symptoms. Her bone biochemistry and hypertension had been well controlled in the 5 years before admission with atenolol 25 mg/day; levothyroxine 75 mcg/day; alfacalcidol 2.25 mcg/day and sandocal 800 mg four times per day. Serum corrected calcium 13 months before admission had been 2.54 mmol/l (normal =2.15-2.6 mmol/l).
At presentation she complained of headache, polydipsia and polyuria. Blood tests showed severe hypercalcaemia (corrected calcium 5.5 mmol/l) and AKI (Table 1) .
Previous and subsequent parathyroid assays (e.g. parathyroid hormone (PTH) 31 December 2009) have confirmed profound hypoparathyroidism. She was treated with intravenous fluids, parenteral bisphosphonates and her exogenous vitamin D (alfacalcidol) and calcium supplements (sandocal) were reduced. An abdominal X-ray demonstrated a visible left kidney with no evidence of nephrocalcinosis. Serum calcium returned to within the normal reference range and has done so on a revised treatment regime-alfacalcidol 1.5 mcg/day and sandocal 800 mg twice daily. In addition, serum creatinine improved to a new baseline of 150 mmol/l. Ultrasonography of her urinary system (Figure 1 ) demonstrated mild nephrocalcinosis (bilateral echogenic areas with a likely 3-mm midpole calculus (arrow) in the left kidney).
The only change in her treatment in the year before presentation was the discontinuation of HRT 2 months before admission.
Discussion
We postulate that the sudden onset of hypercalcaemia in this lady was precipitated by cessation of HRT. Oestrogens and progesterone play an essential 1 The anti-osteoclastic action of oestrogens, via the modulation in osteoblastic production of different substances, such as interleukin-1 and -6, transforming growth factor-b (TGF-b), granulocyte macrophage colony-stimulating factor (GM-CSF), which inhibit osteoclastogenesis and bone resorption activity, is well documented. 2 The direct role in osteoclast inhibition was suggested by the observation that osteoclasts carry oestrogen receptors. Furthermore, in vivo and in vitro data suggest that oestrogens could also have a positive effect on bone formation regulation. 2 We suggest that suspension of HRT in this lady was the cause of her hypercalcaemia, by altering bone calcium metabolism in the direction of increased net loss of calcium from bone. If she had functioning parathyroid tissue, serum calcium levels would have remained constant because the increased calcium movement from bone would have suppressed parathyroid hormone levels. However, the combination of fixed dose calcium and vitamin D supplementation and increased net flux of calcium from bone led to the profound hypercalcaemia. As most of the population have intact parathyroid glands, this is likely to remain a rare complication of HRT cessation. The same phenomenon may occur in renal replacement therapy (RRT) patients who have had a total parathyroidectomy, although the frequent monitoring of bone biochemistry in such cases should preclude the development of such severe hypercalcaemia. In addition, refined surgical techniques for thyroid surgery have led to less parathyroid complications, again making this scenario less prevalent. This unusual case is an interesting manifestation of the known effects of female sex hormones on calcium and bone metabolism.
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